Biocept, Inc. (NASDAQ:BIOC) developers of proprietary circulating tumor cell, is expected to report second quarter earnings results, after market close, on Wednesday 12th August 2020.
Previous Quarter Performance
Biocept, Inc. posted loss for the first quarter of $ 0.11 per share, from the revenue of $ 1.45 million. The quarterly earnings compared with the same quarter last year. According to street consensus, revenue of $ 1.91 million was expected for the first quarter The bottom line results street analysts by $ 0.12 or , at the same time, top line results fell short of analysts by $ 0.46 million or 24.08 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Biocept, Inc.
Stock Performance
According to the previous trading day, closing price of BIOC was $ 1.00, representing a 376.19 % increase from the 52 week low of $ 0.21 and a 23.08 % decrease over the 52 week high of $ 1.30.
The company has a market capital of $ 131.10 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BIOC” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Biocept, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biocept.com
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The companys cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer.
